Dr David Gilham | Vice President of Research and Development
Celyad

Dr David Gilham, Vice President of Research and Development, Celyad

Dr. David Gilham first joined Celyad in April 2016 as member of the Scientific Advisory Board. As from September 1st, 2016, David became Vice-President R&D, heading the implementation of our Research and Development strategy for our programs in immuno-oncology. Dr. Gilham received his Ph.D in Molecular Pharmacology at the University of Dundee prior to moving to Bristol University in 1996 to work on CAR T cells with Professor Robert Hawkins. The group moved to Manchester in 1998 where his research activity has focused on engineering T-cells for cancer therapy and developing the necessary pre-clinical studies to support translation of this therapy into phase I/II clinical trials in Manchester. Prior to joining Celyad, David was a Reader in the Institute of Cancer Sciences, University of Manchester, UK and led the Clinical and Experimental Immunotherapy Group based within the Manchester Cancer Research Centre.

Appearances:



WIC 2017 Day 2, Wednesday 1st November 2017 @ 14:55

NK receptors and CAR T cell therapy: combining innate and adaptive immunity for the immunotherapy of cancer

  • CAR T cells exploiting the natural killer receptor NKG2D (NKR2) provide a broad spectrum of tumor indications that can be targeted by one generic vector.
  • Pre-clinical studies of NKR2 CAR T cells suggest potent anti-tumor activity employing both direct and indirect effector mechanisms of action.
  • Initial clinical trials carried out in the US suggest a good safety profile at low cell doses and some hints of clinical activity.
  • A large US and EU based phase I clinical trial is currently testing NKR2 CAR T cell therapy in haematological and solid tumor indications.
 

back to speakers